ARQT
Price
$13.44
Change
-$1.13 (-7.76%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
1.73B
40 days until earnings call
XENE
Price
$30.74
Change
-$0.85 (-2.69%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
2.41B
33 days until earnings call
Ad is loading...

ARQT vs XENE

Header iconARQT vs XENE Comparison
Open Charts ARQT vs XENEBanner chart's image
Arcutis Biotherapeutics
Price$13.44
Change-$1.13 (-7.76%)
Volume$18.8K
Capitalization1.73B
Xenon Pharmaceuticals
Price$30.74
Change-$0.85 (-2.69%)
Volume$11.01K
Capitalization2.41B
ARQT vs XENE Comparison Chart
Loading...
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARQT vs. XENE commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and XENE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (ARQT: $14.57 vs. XENE: $31.54)
Brand notoriety: ARQT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 151% vs. XENE: 266%
Market capitalization -- ARQT: $1.73B vs. XENE: $2.41B
ARQT [@Biotechnology] is valued at $1.73B. XENE’s [@Biotechnology] market capitalization is $2.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • ARQT’s TA Score: 6 bullish, 4 bearish.
  • XENE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than XENE.

Price Growth

ARQT (@Biotechnology) experienced а -12.23% price change this week, while XENE (@Biotechnology) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

ARQT is expected to report earnings on Aug 13, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.41B) has a higher market cap than ARQT($1.73B). ARQT YTD gains are higher at: 4.594 vs. XENE (-19.541). ARQT has higher annual earnings (EBITDA): -109.63M vs. XENE (-276.74M). XENE has more cash in the bank: 627M vs. ARQT (228M). XENE has less debt than ARQT: XENE (9.02M) vs ARQT (111M). ARQT has higher revenues than XENE: ARQT (197M) vs XENE (0).
ARQTXENEARQT / XENE
Capitalization1.73B2.41B72%
EBITDA-109.63M-276.74M40%
Gain YTD4.594-19.541-24%
P/E RatioN/AN/A-
Revenue197M0-
Total Cash228M627M36%
Total Debt111M9.02M1,231%
FUNDAMENTALS RATINGS
XENE: Fundamental Ratings
XENE
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
37
SMR RATING
1..100
60
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
4
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARQTXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 18 days ago
83%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 7 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSURX50.40N/A
N/A
Goldman Sachs US Equity Insights R
SMCFX58.35N/A
N/A
American Funds SMALLCAP World F2
JVTSX61.81N/A
N/A
Janus Henderson Venture S
LICVX14.06N/A
N/A
Lord Abbett International Equity R6
ETAEX10.06N/A
N/A
Eventide Exponential Technologies A

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with KRYS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+9.63%
KRYS - ARQT
44%
Loosely correlated
+5.97%
IDYA - ARQT
42%
Loosely correlated
+8.69%
CYTK - ARQT
41%
Loosely correlated
+7.90%
ROIV - ARQT
41%
Loosely correlated
+8.70%
BPMC - ARQT
40%
Loosely correlated
+3.59%
More